These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32905646)

  • 1. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
    Buelow DR; Anderson JT; Pounds SB; Shi L; Lamba JK; Hu S; Gibson AA; Goodwin EA; Sparreboom A; Baker SD
    Clin Transl Sci; 2021 Jan; 14(1):137-142. PubMed ID: 32905646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
    Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
    Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
    Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
    Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.
    Drenberg CD; Gibson AA; Pounds SB; Shi L; Rhinehart DP; Li L; Hu S; Du G; Nies AT; Schwab M; Pabla N; Blum W; Gruber TA; Baker SD; Sparreboom A
    Cancer Res; 2017 Apr; 77(8):2102-2111. PubMed ID: 28209616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice.
    Anderson JT; Hu S; Fu Q; Baker SD; Sparreboom A
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00534. PubMed ID: 31832201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
    Oellerich T; Schneider C; Thomas D; Knecht KM; Buzovetsky O; Kaderali L; Schliemann C; Bohnenberger H; Angenendt L; Hartmann W; Wardelmann E; Rothenburger T; Mohr S; Scheich S; Comoglio F; Wilke A; Ströbel P; Serve H; Michaelis M; Ferreirós N; Geisslinger G; Xiong Y; Keppler OT; Cinatl J
    Nat Commun; 2019 Aug; 10(1):3475. PubMed ID: 31375673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpressed mitogen-and stress-activated protein kinase 1 promotes the resistance of cytarabine in acute myeloid leukemia through brahma related gene 1-mediated upregulation of heme oxygenase-1.
    Zhang S; Pan C; Shang Q; Wang W; Hu T; Liu P; Chen S; Wang J; Fang Q
    Eur J Pharmacol; 2022 Feb; 917():174722. PubMed ID: 34953799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
    Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
    Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical update on hypomethylating agents.
    Duchmann M; Itzykson R
    Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
    Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
    Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.
    Carraway HE; Malkaram SA; Cen Y; Shatnawi A; Fan J; Ali HEA; Abd Elmageed ZY; Buttolph T; Denvir J; Primerano DA; Fandy TE
    Sci Rep; 2020 Jun; 10(1):10325. PubMed ID: 32587297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noncanonical immune response to the inhibition of DNA methylation by Staufen1 via stabilization of endogenous retrovirus RNAs.
    Ku Y; Park JH; Cho R; Lee Y; Park HM; Kim M; Hur K; Byun SY; Liu J; Lee YS; Shum D; Shin DY; Koh Y; Cho JY; Yoon SS; Hong J; Kim Y
    Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33762305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia.
    Zhou S; Liu P; Zhang H
    Mol Med Rep; 2017 Jul; 16(1):281-287. PubMed ID: 28498449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia.
    Bhise NS; Elsayed AH; Cao X; Pounds S; Lamba JK
    Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 31022985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
    Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
    Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C).
    Momparler RL; Côté S; Momparler LF
    Leuk Res; 2013 Aug; 37(8):980-4. PubMed ID: 23660386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.
    Zhao W; Wei L; Tan D; Su G; Zheng Y; He C; Mao ZJ; Singleton TP; Yin B
    PLoS One; 2014; 9(10):e109198. PubMed ID: 25314317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
    Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
    Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
    Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP
    Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.